CK Life Sciences International (Holdings), Inc. (0775) AI Stock Analysis

• Market Cap: HK$8.07B
• Dividend Yield: N/A
• Average Volume (3M): 7.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 2.10%
• EPS Growth: -1350.00%
• Country: HK
• Employees: 2,033
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 9,611,072,000
• 10 Day Avg. Volume: 13,068,694
• 30 Day Avg. Volume: 7,559,299
• PEG Ratio: 0.04
• Price to Book (P/B): 1.12
• Price to Sales (P/S): 0.71
• P/FCF Ratio: 25.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: HK$1.00 ▲(20.48% Upside)

The overall stock score of 55 reflects significant profitability challenges and a bearish technical outlook. The company's high leverage and declining equity ratio raise financial stability concerns, while the negative P/E ratio indicates valuation issues. Despite some operational efficiency improvements, the lack of earnings call data and corporate events limits the potential for positive sentiment.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a stable demand for the company's products and suggests potential for future expansion in its markets.

Operational Efficiency

Improved operational efficiency reflects better cost management and resource utilization, which can enhance profitability over the long term.

Positive Cash Flows

Maintaining positive operating cash flow indicates that the company can generate sufficient cash to support its operations, even amid profitability challenges.

Negative Factors

High Leverage

Increased leverage can elevate financial risk and limit the company's ability to invest in growth opportunities, affecting long-term stability.

Profitability Challenges

Ongoing profitability challenges may hinder the company's ability to reinvest in its business and improve shareholder value over time.

Declining Cash Flow

A decline in free cash flow limits the company's capacity to fund new projects or return capital to shareholders, impacting future growth potential.

CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model

Company Description

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, markets, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines. The company is also involved in the contract manufacturing of complementary healthcare medicines, pharmaceutical products, and cosmetics; licensing of registration activities and the importation of finished agricultural goods; holding of land and buildings; financing activities; investment in financial instruments and vineyards; trading of biotechnology products and nutritional supplements; and manufacturing, wholesaling, retailing, and distribution of nutraceutical products. In addition, it distributes turf management machinery, hardware, equipment, and accessories, as well as turf fertilizers, chemicals, and professional pest products; produces, refines, and distributes salt products; and provides research and development services for biotechnology and life sciences technology products. Further, it researches, develops, manufactures, and commercializes drug products to treat pain and melanoma; supplies raw materials for nutritional health, pharmaceutical, cosmetics, personal care, and food segments; and offers packing and asset management services. CK Life Sciences Int'l., (Holdings) Inc. was founded in 1999 and is headquartered in Tai Po, Hong Kong.

How the Company Makes Money

CK Life Sciences generates revenue through several key streams, primarily from the sale of its biotechnology and agricultural products. The company earns income by marketing its proprietary products in various regions, particularly in Asia and other international markets. Significant revenue comes from the sale of plant nutrition and agricultural inputs to farmers and distributors. Additionally, CK Life Sciences engages in partnerships with research institutions and agricultural companies, which can lead to collaborative projects and shared revenue opportunities. The company also invests in research and development to innovate and expand its product offerings, which can enhance its competitive edge and drive future revenue growth.

CK Life Sciences International (Holdings), Inc. Financial Statement Overview

Summary

CK Life Sciences is facing profitability challenges with a negative net income in 2024 despite stable revenue growth. Operational efficiency has improved, but high leverage and a declining equity ratio raise financial stability concerns. Positive operating and free cash flows suggest some operational strength, yet the cash flow decline indicates potential cash management issues.

Income Statement

The company has shown a modest revenue growth of 3.75% from 2023 to 2024. However, it reported a negative net income in 2024, resulting in a net profit margin of -2.29%, indicating profitability challenges. The gross profit margin remained stable at 30.64%, and the EBIT margin improved to 14.18%, suggesting operational efficiency improvements despite bottom-line issues.

Balance Sheet

The debt-to-equity ratio increased to 1.74, indicating a higher leverage, which could pose financial risks. The equity ratio decreased to 32.53%, reflecting a lower proportion of equity financing in the asset structure. ROE turned negative due to the net loss, highlighting the strain on shareholder returns.

Cash Flow

Operating cash flow remained positive, although it decreased by 31.23% from the previous year. Free cash flow declined by 30.74%, suggesting reduced excess cash for reinvestment. The free cash flow to net income ratio is not meaningful due to the negative net income, but the company maintained a positive free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.49B	5.52B	5.32B	5.28B	5.40B	4.94B
Gross Profit	1.69B	1.69B	1.64B	1.63B	1.63B	1.41B
EBITDA	9.39M	337.27M	624.75M	469.51M	449.14M	353.62M
Net Income	-278.39M	-126.55M	17.25M	131.96M	162.80M	125.23M
Balance Sheet
Total Assets	11.29B	10.79B	11.25B	11.27B	11.73B	11.98B
Cash, Cash Equivalents and Short-Term Investments	797.84M	571.21M	676.16M	704.13M	902.47M	971.71M
Total Debt	6.50B	6.10B	5.93B	5.95B	6.21B	6.19B
Total Liabilities	7.63B	7.28B	7.06B	7.11B	7.23B	7.26B
Stockholders Equity	3.65B	3.51B	4.19B	4.16B	4.50B	4.72B
Cash Flow
Free Cash Flow	5.54M	157.00M	222.35M	146.69M	206.33M	151.12M
Operating Cash Flow	202.07M	353.53M	514.18M	363.66M	423.57M	530.96M
Investing Cash Flow	17.52M	-96.64M	-67.96M	-22.12M	-257.88M	-457.31M
Financing Cash Flow	20.56M	-341.98M	-477.95M	-515.34M	-220.08M	168.74M

CK Life Sciences International (Holdings), Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0775, the sentiment is Neutral. The current price of 0.83 is below the 20-day moving average (MA) of 0.84, below the 50-day MA of 0.85, and below the 200-day MA of 0.88, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.30 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0775.

CK Life Sciences International (Holdings), Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	70 Outperform	HK$17.42B	121.79	16.13%	―	48.38%	―
0775	55 Neutral	HK$8.07B	-28.97	-7.26%	―	2.10%	-1350.00%
1672	54 Neutral	HK$13.69B	-48.42	-12.74%	―	-76.58%	-4.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	51 Neutral	HK$10.51B	16.10	35.80%	―	59.70%	239.97%
1477	47 Neutral	HK$6.03B	-20.72	-7.71%	―	74.73%	32.13%

CK Life Sciences International (Holdings), Inc. Corporate Events

CK Life Sciences Subsidiary Reports Encouraging Interim Results for Halneuron® Pain Drug

CK Life Sciences has reported a positive interim clinical update from its majority-owned subsidiary Dogwood Therapeutics, which is running a Phase 2b trial of Halneuron® for chemotherapy-induced neuropathic pain (CINP). An independent statistical review of data from 97 treated patients indicated that Halneuron® is showing a separation from placebo in pain improvement over a four-week period, with the patient group characterized by long-standing CINP and widespread concurrent use of other chronic pain medications. Dogwood also highlighted a notably low dropout rate of about 4.4%, which appears favourable compared with existing FDA-approved chronic pain drugs and supports Halneuron®’s safety and tolerability profile seen in earlier trials. Top-line Phase 2b results are expected in the third quarter of 2026, and while this could strengthen CK Life Sciences’ position in neuropathic pain therapeutics if confirmed and ultimately approved, the company cautions that Halneuron® remains at the mid-stage clinical trial phase with outcomes still subject to further regulatory review and uncertainty for shareholders and potential investors.

The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.

CK Life Sciences Renews Connected Management Services Deal With Cheung Kong Unit

CK Life Sciences has renewed its intra‑group service relationship by having its wholly owned subsidiary, RMSPL, enter into a new management agreement with IPL, a wholly owned subsidiary of Cheung Kong Asset (CKA), to provide comprehensive management, property, leasing, acquisition/disposal and redevelopment services for IPL’s properties in designated territories from 1 January 2026 to 31 December 2028. As IPL is a connected person under Hong Kong listing rules, the arrangement constitutes a continuing connected transaction; however, because the annual caps fall between 0.1% and 5% of the applicable size tests, the deal is subject only to reporting, announcement and annual review requirements and is exempt from independent shareholders’ approval, ensuring continuity of fee income and operational alignment within the group with limited compliance burden.

The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.

CK Life Sciences Announces Board Composition and Roles

CK Life Sciences International (Holdings) Inc. has announced the composition of its board of directors and their roles within the company. The board includes a mix of executive and non-executive directors, with various members serving on committees such as the Audit, Remuneration, Nomination, Sustainability, and Executive Committees. This announcement provides stakeholders with insights into the company’s governance structure, potentially impacting its strategic direction and operational management.

The most recent analyst rating on (HK:0775) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on CK Life Sciences International (Holdings), Inc. stock, see the HK:0775 Stock Forecast page.